Generation of a human iPSC line (CIBi014-A) from a patient with Parkinson's disease carrying a novel heterozygotic PARK8 (LRRK2) mutation

doi:10.1016/j.scr.2022.102995

. 2023 Feb:66:102995.

doi: 10.1016/j.scr.2022.102995. Epub 2022 Dec 9.

Generation of a human iPSC line (CIBi014-A) from a patient with Parkinson's disease carrying a novel heterozygotic PARK8 (LRRK2) mutation

Lingfei Li¹, Xiaoli Si², Jiayin Yang³, Meng Lei⁴, Huifang Liu⁵, Jie Ruan⁶, Hanting Fu⁷, Wenxuan Li⁷, Hui Yang¹, Xiaoguang Lei⁸, Hongfei Sang⁹

Affiliations

¹ Department of Neurology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
² Department of Neurology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.
³ Laboratory of iPSC and Disease Models, Cell Inspire Biotechnology Co., Ltd., Shenzhen, 518101, China.
⁴ Department of Neurology, The Third People's Hospital of Henan Province, Zhengzhou 450000, China.
⁵ Division of Neurology, Department of Medicine, University of Hong Kong, Hong Kong.
⁶ Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
⁷ The 1(st) School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou 325000, China.
⁸ Department of Neurology, First Affiliated Hospital of Kunming Medical University, No.1 School of Clinical Medicine, Kunming Medical University, Kunming 650500, China. Electronic address: leixiaoguang@zju.edu.cn.
⁹ Department of Neurology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China. Electronic address: sanghongfei1988@163.com.

PMID: 36528012
DOI: 10.1016/j.scr.2022.102995

Free article

Generation of a human iPSC line (CIBi014-A) from a patient with Parkinson's disease carrying a novel heterozygotic PARK8 (LRRK2) mutation

Lingfei Li et al. Stem Cell Res. 2023 Feb.

Free article

. 2023 Feb:66:102995.

doi: 10.1016/j.scr.2022.102995. Epub 2022 Dec 9.

Authors

Lingfei Li¹, Xiaoli Si², Jiayin Yang³, Meng Lei⁴, Huifang Liu⁵, Jie Ruan⁶, Hanting Fu⁷, Wenxuan Li⁷, Hui Yang¹, Xiaoguang Lei⁸, Hongfei Sang⁹

Affiliations

¹ Department of Neurology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
² Department of Neurology, the Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310000, China.
³ Laboratory of iPSC and Disease Models, Cell Inspire Biotechnology Co., Ltd., Shenzhen, 518101, China.
⁴ Department of Neurology, The Third People's Hospital of Henan Province, Zhengzhou 450000, China.
⁵ Division of Neurology, Department of Medicine, University of Hong Kong, Hong Kong.
⁶ Department of Clinical Pharmacy, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China.
⁷ The 1(st) School of Medicine, School of Information and Engineering, Wenzhou Medical University, Wenzhou 325000, China.
⁸ Department of Neurology, First Affiliated Hospital of Kunming Medical University, No.1 School of Clinical Medicine, Kunming Medical University, Kunming 650500, China. Electronic address: leixiaoguang@zju.edu.cn.
⁹ Department of Neurology, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine, Hangzhou 310000, China. Electronic address: sanghongfei1988@163.com.

PMID: 36528012
DOI: 10.1016/j.scr.2022.102995

Abstract

Leucine-rich repeat kinase 2 (LRRK2), also known as Dardarin (derived from the Basque word "dardara," meaning tremor), is a protein kinase encoded by the PARK8 gene. This protein is mainly distributed in the cytoplasm; however, it is also present in the mitochondrial outer membrane. Mutations in the LRRK2 protein cause Parkinson's disease (PD). We generated a human induced pluripotent stem cell (iPSC) line (CIBi014-A) expressing pluripotency markers. This cell line exhibited a normal karyotype and could be differentiated into three germ layers in vitro. This line will be valuable for investigating the mechanism underlying PD and identifying potential therapeutic targets.

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
- Elsevier Science
Medical
- MedlinePlus Health Information
Research Materials
- Cellosaurus - a cell line knowledge resource

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Generation of a human iPSC line (CIBi014-A) from a patient with Parkinson's disease carrying a novel heterozygotic PARK8 (LRRK2) mutation

Affiliations

Generation of a human iPSC line (CIBi014-A) from a patient with Parkinson's disease carrying a novel heterozygotic PARK8 (LRRK2) mutation

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Publication types

MeSH terms

Substances

LinkOut - more resources

Full Text Sources

Medical

Research Materials

Abstract

Conflict of interest statement

Similar articles

Publication types

MeSH terms

Substances

Related information

LinkOut - more resources

Full Text Sources

Medical

Research Materials